Literature DB >> 11250970

Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation.

A Nabar1, L M Rodriguez, C Timmermans, R van Mechelen, H J Wellens.   

Abstract

OBJECTIVE: To describe the electrocardiographic and electrophysiological findings of new atrial flutter developing in patients taking class IC antiarrhythmic drugs for recurrent atrial fibrillation, and to report the long term results of right atrial isthmus ablation in relation to the ECG pattern of spontaneous atrial flutter.
DESIGN: Retrospective analysis.
SETTING: Tertiary care academic hospital. PATIENTS: 24 consecutive patients with atrial fibrillation (age 54 (12) years; 5 female, 19 male) developing atrial flutter while taking propafenone (n = 12) or flecainide (n = 12).
RESULTS: The ECG was classified as typical (n = 13; 54%) or atypical atrial flutter (n = 8) or coarse atrial fibrillation (n = 3). Counterclockwise atrial flutter was the predominant arrhythmia. Acute success after isthmus ablation was similar in patients with typical (12/13) and atypical (8/8) atrial flutter. After long term follow up (13 (6) months, range 6-26 months), continuation of antiarrhythmic drug treatment appeared to result in better control of recurrences of atrial fibrillation in patients with typical atrial flutter (11/13) than in those with atypical atrial flutter (4/8), but the difference was not significant. Ablation for coarse atrial fibrillation was unsuccessful.
CONCLUSIONS: New atrial flutter developing in patients taking class IC antiarrhythmic drugs for recurrent atrial fibrillation has either typical or atypical flutter wave morphology on ECG. The endocardial activation pattern and the acute results of ablation suggest that the flutter circuit was located in the right atrium and that the isthmus was involved in the re-entry mechanism. There appeared to be better long term control of recurrent atrial fibrillation in patients with typical (85%) as compared with atypical atrial flutter (50%). Patients developing coarse atrial fibrillation may not be candidates for this strategy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250970      PMCID: PMC1729704          DOI: 10.1136/heart.85.4.424

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  13 in total

1.  The architecture of the atrial musculature between the orifice of the inferior caval vein and the tricuspid valve: the anatomy of the isthmus.

Authors:  J A Cabrera; D Sanchez-Quintana; S Y Ho; A Medina; R H Anderson
Journal:  J Cardiovasc Electrophysiol       Date:  1998-11

2.  Radiofrequency catheter ablation of atrial flutter. Further insights into the various types of isthmus block: application to ablation during sinus rhythm.

Authors:  H Poty; N Saoudi; M Nair; F Anselme; B Letac
Journal:  Circulation       Date:  1996-12-15       Impact factor: 29.690

3.  Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation.

Authors:  D T Huang; K M Monahan; P Zimetbaum; P Papageorgiou; L M Epstein; M E Josephson
Journal:  J Cardiovasc Electrophysiol       Date:  1998-05

4.  Isoproterenol to evaluate resumption of conduction after right atrial isthmus ablation in type I atrial flutter.

Authors:  A Nabar; L M Rodriguez; C Timmermans; J L Smeets; H J Wellens
Journal:  Circulation       Date:  1999-06-29       Impact factor: 29.690

5.  Importance of atrial flutter isthmus in postoperative intra-atrial reentrant tachycardia.

Authors:  D P Chan; G F Van Hare; J A Mackall; M D Carlson; A L Waldo
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

6.  A focal source of atrial fibrillation treated by discrete radiofrequency ablation.

Authors:  P Jaïs; M Haïssaguerre; D C Shah; S Chouairi; L Gencel; M Hocini; J Clémenty
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

7.  Role of anisotropy in determining the selective action of antiarrhythmics in atrial flutter in the dog.

Authors:  T Yamashita; H Inoue; A Nozaki; T T Kuo; M Usui; T Sugimoto
Journal:  Cardiovasc Res       Date:  1992-03       Impact factor: 10.787

8.  High-density mapping of electrically induced atrial fibrillation in humans.

Authors:  K T Konings; C J Kirchhof; J R Smeets; H J Wellens; O C Penn; M A Allessie
Journal:  Circulation       Date:  1994-04       Impact factor: 29.690

9.  New electrocardiographic criteria for the differentiation between counterclockwise and clockwise atrial flutter: correlation with electrophysiological study and radiofrequency catheter ablation.

Authors:  L P Lai; J L Lin; L J Lin; W J Chen; Y L Ho; Y Z Tseng; C H Chen; Y T Lee; W P Lien; S K Huang
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

10.  Atrial activation sequence during atrial flutter in the canine pericarditis model and its effects on the polarity of the flutter wave in the electrocardiogram.

Authors:  K Okumura; V J Plumb; P L Pagé; A L Waldo
Journal:  J Am Coll Cardiol       Date:  1991-02       Impact factor: 24.094

View more
  12 in total

Review 1.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

2.  Pharmacological and ablative hybrid therapy of atrial fibrillation. Long-term effect on quality of life and arrhythmia-related symptoms.

Authors:  H Bielik; J Schrickel; N Shlevkov; A Yang; J O Schwab; A Bitzen; B Lüderitz; T Lewalter
Journal:  Z Kardiol       Date:  2005-09

Review 3.  Typical Flutter Ablation as an Adjunct to Catheter Ablation of Atrial Fibrillation.

Authors:  Dipen Shah
Journal:  J Atr Fibrillation       Date:  2008-12-01

4.  Nearly uniform failure of atrial flutter ablation and continuation of antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation.

Authors:  Nicholas Anastasio; David S Frankel; Marc W Deyell; Erica Zado; Edward P Gerstenfeld; Sanjay Dixit; Joshua Cooper; David Lin; Francis E Marchlinski; David J Callans
Journal:  J Interv Card Electrophysiol       Date:  2012-05-04       Impact factor: 1.900

Review 5.  Drug-induced atrial fibrillation.

Authors:  Yaman Kaakeh; Brian R Overholser; John C Lopshire; James E Tisdale
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

6.  Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study.

Authors:  Aditya J Ullal; Claire T Than; Jun Fan; Susan Schmitt; Alexander C Perino; Daniel W Kaiser; Paul A Heidenreich; Susan M Frayne; Ciaran S Phibbs; Mintu P Turakhia
Journal:  Am Heart J       Date:  2015-07-26       Impact factor: 4.749

Review 7.  Atrial-selective sodium channel block for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191

8.  The effects of a bidirectional cavo-tricuspid isthmus block in persistent atrial fibrillation.

Authors:  Jin-Bae Kim; Seonghoon Choi; Boyoung Joung; Moon-Hyoung Lee; Sung-Soon Kim
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

9.  Colchicine modulates calcium homeostasis and electrical property of HL-1 cells.

Authors:  Yen-Yu Lu; Yao-Chang Chen; Yu-Hsun Kao; Yung-Kuo Lin; Yung-Hsin Yeh; Shih-Ann Chen; Yi-Jen Chen
Journal:  J Cell Mol Med       Date:  2016-02-29       Impact factor: 5.310

Review 10.  Revisiting an Underrecognized Strategy for Rhythm Management: Hybrid Therapy for Patients who Convert from Atrial Fibrillation to Flutter on Antiarrhythmic Drugs.

Authors:  Fady S Riad; Albert L Waldo
Journal:  J Innov Card Rhythm Manag       Date:  2019-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.